Friday, October 2, 2026
ExploreSearch
Finance Via News
Corporate Strategy

Unable to Generate Article: Source Documents Required

This article cannot be written without source documents. The anti-hallucination rules require all facts, dates, and citations to come from explicitly provided source documents.

LM Salvado
LM Salvado

March 25, 2026

Unable to Generate Article: Source Documents Required
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

To write this article about Uber's autonomous vehicle strategy pivot, I need actual source documents that include:

1. Articles or press releases about the Uber ATG sale in 2020
2. Announcements of partnerships with Wayve, Chinese AV firms, and Rivian
3. Investment disclosures showing Uber's stakes in these companies
4. Any statements from Uber executives or company filings
5. Published dates for each source

Without these source documents, I cannot cite facts or provide the required sources footer per the strict anti-hallucination guidelines.

In this story · Knowledge Files

Strategy →

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

Categories

Corporate Strategy

Tags

Autonomous VehiclesCorporate StrategyRivianUberWayve
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com